A PHP Error was encountered

Severity: Warning

Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests

Filename: helpers/my_audit_helper.php

Line Number: 176

Backtrace:

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3122
Function: getPubMedXML

File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global

File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword

File: /var/www/html/index.php
Line: 316
Function: require_once

Triple-combination therapy did not improve prognosis in anti-MDA5 positive dermatomyositis: a multicentre longitudinal cohort study. | LitMetric

AI Article Synopsis

  • The study investigates the effectiveness and safety of a triple-combination therapy (high-dose corticosteroids, tacrolimus, and intravenous cyclophosphamide) for patients with anti-melanoma differentiation-associated gene 5-positive dermatomyositis (MDA5+ DM) who have interstitial lung disease (ILD).
  • Despite hopes for positive outcomes, the therapy did not improve patient prognosis and was associated with higher mortality, particularly in high-risk patients with rapidly progressive ILD (RP-ILD).
  • The findings indicate that this treatment may not be beneficial for MDA5+ DM patients, highlighting the need for further research to find safer and more effective therapies for this condition.

Article Abstract

Objectives: Anti-melanoma differentiation-associated gene 5-positive dermatomyositis (MDA5+ DM) is frequently linked with interstitial lung disease (ILD), especially the rapidly progressive ILD (RP-ILD). We conduct this research to evaluate the efficacy and safety of triple-combination (triple-combo) therapy consisting of high-dose corticosteroids, tacrolimus and intravenous cyclophosphamide in treating MDA5+ DM patients with ILD.

Methods: A multicentre longitudinal cohort study involving 115 MDA5+ DM patients from the Nanjing Medical University Myositis Associated ILD (NMMI) cohort was conducted between January 2019 and November 2022. Patients were categorised into triple-combo and non-triple therapy groups, and their outcomes were assessed.

Results: Contrary to expectations, triple-combo therapy did not improve the prognosis for MDA5+ DM patients but was linked to increased mortality rates, especially among those at high risk for RP-ILD.

Conclusions: Our study suggests that triple-combo therapy might not be effective in improving prognosis in MDA5+ DM patients. Further research is needed to establish safer and more effective treatment modalities for this patient population.

Download full-text PDF

Source
http://dx.doi.org/10.55563/clinexprheumatol/jmpuxaDOI Listing

Publication Analysis

Top Keywords

mda5+ patients
16
triple-combo therapy
12
therapy improve
8
improve prognosis
8
multicentre longitudinal
8
longitudinal cohort
8
cohort study
8
prognosis mda5+
8
mda5+
5
patients
5

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!